← All trials
NCT05168683
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 11, 2022
- Primary completion
- Dec 30, 2022
- Completion date
- Dec 30, 2022
- First posted
- Dec 23, 2021
- Last posted
- Jul 26, 2022
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Allena PharmaceuticalsLead sponsor
- Allena PharmaceuticalsStudy director
- BDD Pharma LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.